All for Joomla All for Webmasters

Hemostasis and COVID-19

Rate this item
(3 votes)

200 tripodi

Prof. Armando Tripodi

 

  • Full Professor of Clinical Biochemistry at Humanitas University, Milano
  • Researcher in the Thrombosis and Hemostasis field at Angelo Bianchi Bonomi Hemophilia and Thrombosis Center
  • Current President of the Italian Society of Thrombosis and Hemostasis (SISET)
  • Previously Co-Chairman of ‘Control of Anticoagulation’ and ‘Lupus Anticoagulant/Phospholipid-dependent Antibodies’ SSC at ISTH
  • Previously president of the Italian Federation of Anticoagulation Clinics (FCSA)
  • Coordinator of WHO for preparation and standardization of IRP (rTF/95, RBT/05 e rTF/09) for Warfarin therapy control
  • Previously Associate Editor and advisory board member of the Journal of Thrombosis and Hemostasis (JTH)
  • Author of guidelines for anticoagulation control for the Italian Society for Thrombosis and Hemostasis (SISET) and for WHO
  • More than 400 publications

 

Questions/answers on the Coagulopathy of COVID-19

A1. D dimer as well the other basic tests of coagulation (PT, APTT, fibrinogen and platelet count) should be performed on a daily basis, especially in the most severe patients.

A2. There are no established cut off values based on prospective observations for D dimer to assess the severity of COVID-19. Empirically, it can be considered that the higher the value the higher the severity.

A3. VTE in outpatients can be excluded if D dimer levels are below the cut off and the pre-test clinical probability of VTE (determined by the Wells score) is unlikely. Beside the difficulty of collecting the Wells score in COVID-19 patients, most of the patients would have D dimer levels which are far higher than the usual cut off. Compression ultrasonography or CT scan should be used to diagnose deep vein thrombosis or pulmonary embolism in COVID-19 patients.

A4. There are no established and validated algorithms to adjust the dosage of heparin in COVID-19 patients based on the value of D dimer. Clinical trials are needed to resolve this issue.

A5. I agree that APTT is not strictly needed, but being one of the basic tests of coagulation, relatively cheap and easy to run I cannot see reasons to omit this test.

A6. All the issues mentioned in this question might be relevant and need to be addressed by specific testing on frozen plasma collected from COVID-19 patients.

A7. Whenever standard prophylaxis is used to prevent VTE, there is no need for laboratory monitoring as both LMWH and UFH can be used at fixed dose. Whenever patients are treated to cure acute VTE, laboratory monitoring should be done preferably with the anti-FXa assay (mandatory for UFH). Presently there are no established and validated therapeutic intervals for COVID-19 patients. Until COVID-19 specific therapeutic intervals are established, one should refer to those used for other patients.

A8. Although there are no specific observations reported from clinical practice and the literature, HIT could be a relevant issue in COVID-19 patients.

A9. Composite question. Anti-platelet drugs should be considered, especially if patients were on treatment because of cardiovascular disease before COVID-19. tPA could be used in special conditions (on case by case basis) to treat massive pulmonary embolism in patients deemed at low risk of hemorrhage. Finally, DOAC can be used in COVID-19 patients, but interferences of DOAC with antiviral treatment have been reported (antiviral drugs are likely to increase the plasma DOAC concentration) and therefore physicians may prefer to switch to LMWH. If not, close monitoring of plasma DOAC concentrations would be required.

A10. Most of the issues related to the derangement of hemostasis and the prevention/ treatment of VTE are still uncertain.

Additional Info

Read 2810 times

Werfen.com. All rights Reserved. Privacy Policy | Cookies Policy | Terms of Service

No Internet Connection